[1]白梦雪 赵慧强.低分子右旋糖酐光学相干断层成像技术在冠状动脉疾病中的应用进展[J].心血管病学进展,2022,(2):103.[doi:10.16806/j.cnki.issn.1004-3934.20.02.003]
 BAI MengxueZHAO Huiqiang.Application of Low Molecular Dextran Optical Coherence Tomography?n Coronary Arteries Disease[J].Advances in Cardiovascular Diseases,2022,(2):103.[doi:10.16806/j.cnki.issn.1004-3934.20.02.003]
点击复制

低分子右旋糖酐光学相干断层成像技术在冠状动脉疾病中的应用进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年2期
页码:
103
栏目:
综述
出版日期:
2022-02-25

文章信息/Info

Title:
Application of Low Molecular Dextran Optical Coherence Tomography?n Coronary Arteries Disease
作者:
白梦雪1 赵慧强12
(1.首都医科大学研究生院,北京100069;2.首都医科大学附属北京友谊医院心血管中心,北京 100050)
Author(s):
BAI Mengxue1ZHAO Huiqiang12
1.Capital Medical University Graduate SchoolBeijing 100069,China; 2.Cardiovascular Center,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China)
关键词:
低分子右旋糖光学相干断层成像冠状动脉
Keywords:
Low molecular weight dextranOptical coherence tomographyCoronary artery
DOI:
10.16806/j.cnki.issn.1004-3934.20.02.003
摘要:
光学相干断层成像(OCT)是一门新兴的血管内成像技术,是以反射近红外线代替反射超声波对生物组织进行成像,在冠心病诊疗中具有重要的应用价值。操作最大的缺点是注射对比剂,过多的对比剂会增加对比剂肾病风险,非对比剂(如分子右旋糖)可能代替对比剂冲洗血液来实现。现就分子右旋糖酐技术在冠状动脉疾病中的应用研究做一综述。
Abstract:
Optical coherence tomography is an emerging new technology of intravascular imaging,which uses reflected near-infrared ray instead of reflected ultrasound to image biological tissues,and has important application value in the diagnosis and treatment of coronary heart disease. However,the major drawback of OCT operations is that it requires injection of contrast agent. Excessive contrast agent can increase the risk of contrast induced nephropathy. It is likely that non-contrast agent (such as low molecular weight dextran) replace contrast agent to flush the blood for OCT imaging. This article reviews the application of low molecular weight dextran for OCT in coronary artery disease

参考文献/References:

[1] Terashima M,Kaneda H,Suzuki T. The role of optical coherence tomography in coronary intervention[J]. Korean J Intern Med,2012,27(1):1-12.
[2] Simard T,Motazedian P,Majeed K,et al. Contrast-free optical coherence tomography:systematic evaluation of non-contrast media for intravascular assessment[J]. PLoS One,2020,15(8):e0237588.
[3] Swanson EA,Huang D,Hee MR,et al. High-speed optical coherence domain reflectometry[J]. Opt Lett,1992,17(2):151-153.
[4] Patwari P,Weissman NJ,Boppart SA,et al. Assessment of coronary plaque with optical coherence tomography and high-frequency ultrasound[J]. Am J Cardiol,2000,85(5):641-644.
[5] Jang IK,Bouma BE,Kang DH,et al. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography:comparison with intravascular ultrasound[J]. J Am Coll Cardiol,2002,39(4):604-609.
[6] Kume T,Akasaka T,Kawamoto T,et al. Assessment of coronary arterial plaque by optical coherence tomography[J]. Am J Cardiol,2006,97(8):1172-1175.
[7] Naghavi M,Libby P,Falk E,et al. From vulnerable plaque to vulnerable patient:a call for new definitions and risk assessment strategies:Part I[J]. Circulation,2003,108(14):1664-1672.
[8] Davies MJ,Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death[J]. N Engl J Med,1984,310(18):1137-1140.
[9] Falk E,Shah PK,Fuster V. Coronary plaque disruption[J]. Circulation,1995,92(3):657-671.
[10] Ali ZA,Maehara A,Généreux P,et al. Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIENⅢ:OPTIMIZE PCI):a randomised controlled trial[J]. Lancet,2016,388(10060):2618-2628.
[11] Kuku KO,Ekanem E,Azizi V,et al. Optical coherence tomography-guided percutaneous coronary intervention compared with other imaging guidance:a meta-analysis[J]. Int J Cardiovasc Imaging,2018,34(4):503-513.
[12] Won H,Shin DH,Kim BK,et al. Optical coherence tomography derived cut-off value of uncovered stent struts to predict adverse clinical outcomes after drug-eluting stent implantation[J]. Int J Cardiovasc Imaging,2013,29(6):1255-1263.
[13] Finn AV,Joner M,Nakazawa G,et al. Pathological correlates of late drug-eluting stent thrombosis:strut coverage as a marker of endothelialization[J]. Circulation,2007,115(18):2435-2441.
[14] Matsumoto D,Shite J,Shinke T,et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up:evaluated by optical coherence tomography[J]. Eur Heart J,2007,28(8):961-967.
[15] 中华医学会心血管病学分会介入心脏病学组,心血管病影像学组光学相干断层成像技术在冠心病介入诊疗领域的应用中国专家建议[J]. 中华心血管病杂志2017,45(1):5-12.
[16] Parsa P,Jacques SL,Nishioka NS. Optical properties of rat liver between 350 and 2200 nm[J]. Appl Opt,1989,28(12):2325-2330.
[17] Xu X,Wang RK,Elder JB,et al. Effect of dextran-induced changes in refractive index and aggregation on optical properties of whole blood[J]. Phys Med Biol,2003,48(9):1205-1221.
[18] Takarada S,Imanishi T,Liu Y,et al. Advantage of next-generation frequency-domain optical coherence tomography compared with conventional time-domain system in the assessment of coronary lesion[J]. Catheter Cardiovasc Interv,2010,75(2):202-206.
[19] Tearney GJ,Waxman S,Shishkov M,et al. Three-dimensional coronary artery microscopy by intracoronary optical frequency domain imaging[J]. JACC Cardiovasc Imaging,2008,1(6):752-761.
[20] Prati F,Jenkins MW,di Giorgio A,et al. Intracoronary optical coherence tomography,basic theory and image acquisition techniques[J]. Int J Cardiovasc Imaging,2011,27(2):251-258.
[21] Andreucci M,Solomon R,Tasanarong A. Side effects of radiographic contrast media:pathogenesis,risk factors,and prevention[J]. Biomed Res Int,2014,2014:741018.
[22] Mehran R,Aymong ED,Nikolsky E,et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention:development and initial validation[J]. J Am Coll Cardiol,2004,44(7):1393-1399.
[23] Zeng JF,Chen SQ,Ye JF,et al. A simple risk score model for predicting contrast-induced nephropathy after coronary angiography in patients with diabetes[J]. Clin Exp Nephrol,2019,23(7):969-981.
[24] Mitra S,Khandelwal P. Are all colloids same? How to select the right colloid?[J]. Indian J Anaesth,2009,53(5):592-607.
[25] Varrier M,Ostermann M. Fluid composition and clinical effects[J]. Crit Care Clin,2015,31(4):823-837.
[26] Jones CI,Payne DA,Hayes PD,et al. The antithrombotic effect of dextran-40 in man is due to enhanced fibrinolysis in vivo[J]. J Vasc Surg,2008,48(3):715-722.
[27] van der Linden P,Ickx BE. The effects of colloid solutions on hemostasis[J]. Can J Anaesth,2006,53(6 Suppl):S30-S39.
[28] Nearman HS,Herman ML. Toxic effects of colloids in the intensive care unit[J]. Crit Care Clin,1991,7(3):713-723.
[29] Xu X,Yu L,Chen Z. Optical clearing of flowing blood using dextrans with spectral domain optical coherence tomography[J]. J Biomed Opt,2008,13(2):021107.
[30] Li J,Minami H,Steward E,et al. Optimal flushing agents for integrated optical and acoustic imaging systems[J]. J Biomed Opt,2015,20(5):56005.
[31] Vijayvergiya R,Ratheesh KJ,Gupta A. Low molecular weight dextran:an alternative to radiographic contrast agent for optical coherence tomography imaging[J]. IHJ Cardiovascular Case Reports (CVCR),2017,1(1):10-11.
[32] Ozaki Y,Kitabata H,Tsujioka H,et al. Comparison of contrast media and low-molecular-weight dextran for frequency-domain optical coherence tomography[J]. Circ J,2012,76(4):922-927.
[33] Frick K,Michael TT,Alomar M,et al. Low molecular weight dextran provides similar optical coherence tomography coronary imaging compared to radiographic contrast media[J]. Catheter Cardiovasc Interv,2014,84(5):727-731.
[34] Kendrick DE,Allemang MT,Gosling AF,et al. Dextran or saline can replace contrast for intravascular optical coherence tomography in lower extremity arteries[J]. J Endovasc Ther,2016,23(5):723-730.
[35] Azzalini L,Mitomo S,Hachinohe D,et al. Zero-contrast percutaneous coronary intervention guided by dextran-based optical coherence tomography[J]. Can J Cardiol,2018,34(3):342.e1-342.e3.
[36] Vasu N,Subban V,Ajit Mullasari S. Zero contrast optical coherence tomography-guided percutaneous coronary intervention for in-stent restenosis of the saphenous vein graft using a non-contrast flush medium[J]. Indian Heart J,2018,70(Suppl 3):S492-S495.
[37] Kurogi K,Ishii M,Sakamoto K,et al. Minimum-contrast percutaneous coronary intervention guided by optical coherence tomography using low-molecular weight dextran[J]. JACC Cardiovasc Interv,2020,13(10):1270-1272.
[38] Misawa T,Sugiyama T,Kanaji Y,et al. Effect of contrast medium versus low-molecular-weight dextran for intracoronary optical coherence tomography in renal insufficiency[J]. Int J Cardiovasc Imaging,2021,37(9):2603-2615.

相似文献/References:

[1]鲁鹏,综述,蔡琳,等.冠状动脉钙化的研究新进展[J].心血管病学进展,2016,(2):176.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.021]
 LU Peng,CAI Lin,HUANG Wei.New Progress of Coronary Artery Calcification[J].Advances in Cardiovascular Diseases,2016,(2):176.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.021]
[2]郑剑峰 邱洪.冠状动脉钙化研究进展[J].心血管病学进展,2020,(4):338.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.002]
 ZHENG JianFengQIU Hong.Coronary Artery Calcification[J].Advances in Cardiovascular Diseases,2020,(2):338.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.002]
[3]孙一博 孙莉萍 董建增.血管炎的冠状动脉风险及手术治疗进展[J].心血管病学进展,2020,(8):821.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.010]
 SUN YiboSUN LipingDONG Jianzeng.Coronary Risk and Progress in Surgical Therapy of Vasculitis[J].Advances in Cardiovascular Diseases,2020,(2):821.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.010]
[4]田婷 罗俊一 杨毅宁.一种罕见的冠状动脉异常——编织样冠状动脉[J].心血管病学进展,2020,(9):943.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.014]
 TIAN Ting,LUO Junyi,YANG Yining.An Extremely Rare Anomaly of Coronary Artery[J].Advances in Cardiovascular Diseases,2020,(2):943.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.014]
[5]陈璐 王国宏 郭彩霞.冠状动脉CT血管成像对冠心病预后预测价值及治疗策略指导意义[J].心血管病学进展,2022,(2):108.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.004]
 CHEN Lu,WANG Guohong,GUO Caixia.The Value of Coronary CT Angiography In Predicting the Prognosis and Treatment Strategies of Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2022,(2):108.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.004]
[6]李俊鹏 刘建 刘娜 杨欣荣 高婷 赵正凯.“三低”技术在CT体部血管一站式成像的应用价值[J].心血管病学进展,2022,(7):662.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
 LI Junpeng,LIU Jian,LIU Na,et al.Application of Three Lows Technology in One-Stop Imaging of CT Body Vessels[J].Advances in Cardiovascular Diseases,2022,(2):662.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[7]李依珂 高艳香 李青 郭紫玉 郑金刚.冠状动脉微循环侵入性检测方法研究进展[J].心血管病学进展,2023,(1):30.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.008]
 LI Yike,GAO Yanxiang,LI Qing,et al.Invasive Assessment of Coronary Microcirculation[J].Advances in Cardiovascular Diseases,2023,(2):30.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.008]
[8]李明 张慧平.急性ST段抬高心肌梗死患者直接经皮冠状动脉介入治疗后微血管功能障碍再认识[J].心血管病学进展,2023,(3):193.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.001]
 LI Ming,ZHANG Huiping.Coronary Microvascular Dysfunction in Patients with Acute ST Segment?levation Myocardial Infarction After Primary Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2023,(2):193.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.001]
[9]徐明成 赵玉娟.甘油三酯葡萄糖指数对动脉粥样硬化性心血管疾病的预测价值[J].心血管病学进展,2023,(9):810.[doi:10.16806/j.cnki.issn.1004-3934.202.09.010]
 Xu Mingcheng,ZHAO Yujuan.Predictive Value of Triglyceride Glucose Index in Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2023,(2):810.[doi:10.16806/j.cnki.issn.1004-3934.202.09.010]

更新日期/Last Update: 2022-08-19